6-Diazo-5-oxo-l-norleucine (DON) is a glutamine antagonist with robust anticancer efficacy; however, its therapeutic potential was hampered by its biodistribution and toxicity to normal tissues, specifically gastrointestinal (GI) tissues. To circumvent DON's toxicity, we synthesized a series of tumor-targeted DON prodrugs designed to circulate inert in plasma and preferentially activate over DON in tumor. Our best prodrug 6 (isopropyl 2-(6-acetamido-2-(adamantane-1-carboxamido)hexanamido)-6-diazo-5-oxohexanoate) showed stability in plasma, liver, and intestinal homogenates yet was readily cleaved to DON in P493B lymphoma cells, exhibiting a 55-fold enhanced tumor cell-to-plasma ratio versus that of DON and resulting in a dose-dependent inhibition of cell proliferation. Using carboxylesterase 1 knockout mice that were shown to mimic human prodrug metabolism, systemic administration of 6 delivered 11-fold higher DON exposure to tumor (target tissue; AUC0- t = 5.1 nmol h/g) versus GI tissues (toxicity tissue; AUC0- t = 0.45 nmol h/g). In summary, these studies describe the discovery of a glutamine antagonist prodrug that provides selective tumor exposure.

Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech Republic v v i Prague 166 10 Czech Republic

Zobrazit více v PubMed

Reitzer LJ; Wice BM; Kennell D Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J. Biol. Chem. 1979, 254, 2669–2676. PubMed

Wise DR; DeBerardinis RJ; Mancuso A; Sayed N; Zhang XY; Pfeiffer HK; Nissim I; Daikhin E; Yudkoff M; McMahon SB; Thompson CB Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 18782–18787. PubMed PMC

Liu W; Le A; Hancock C; Lane AN; Dang CV; Fan TW; Phang JM Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 8983–8988. PubMed PMC

Ahluwalia GS; Grem JL; Hao Z; Cooney DA Metabolism and action of amino acid analogue anti-cancer agents. Pharmacol. Ther. 1990, 46, 243–271. PubMed

Thangavelu K; Chong QY; Low BC; Sivaraman J Structural basis for the active site inhibition mechanism of human kidney-type glutaminase (KGA). Sci. Rep. 2014, 4, No. 3827. PubMed PMC

Tran TQ; Ishak Gabra MB; Lowman XH; Yang Y; Reid MA; Pan M; O’Connor TR; Kong M Glutamine deficiency induces DNA alkylation damage and sensitizes cancer cells to alkylating agents through inhibition of ALKBH enzymes. PLoS Biol. 2017, 15, No. e2002810. PubMed PMC

Magill GB; Myers WP; Reilly HC; Putnam RC; Magill JW; Sykes MP; Escher GC; Karnofsky DA; Burchenal JH Pharmacological and initial therapeutic observations on 6-diazo-5-oxo-1-norleucine (DON) in human neoplastic disease. Cancer 1957, 10, 1138–1150. PubMed

Sullivan MP; Nelson JA; Feldman S; Van Nguyen B Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-l-norleucine) in children. Cancer Chemother. Pharmacol. 1988, 21, 78–84. PubMed

Earhart RH; Amato DJ; Chang AY; Borden EC; Shiraki M; Dowd ME; Comis RL; Davis TE; Smith TJ Phase II trial of 6-diazo-5-oxo-l-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas. Invest. New Drugs 1990, 8, 113–119. PubMed

Rahman A; Smith FP; Luc PT; Woolley PV Phase I study and clinical pharmacology of 6-diazo-5-oxo-l-norleucine (DON). Invest. New Drugs 1985, 3, 369–374. PubMed

Eagan RT; Frytak S; Nichols WC; Creagan ET; Ingle JN Phase II study on DON in patients with previously treated advanced lung cancer. Cancer Treat. Rep. 1982, 66, 1665–1666. PubMed

Earhart RH; Koeller JM; Davis HL Phase I trial of 6-diazo-5-oxo-l-norleucine (DON) administered by 5-day courses. Cancer Treat. Rep. 1982, 66, 1215–1217. PubMed

Kovach JS; Eagan RT; Powis G; Rubin J; Creagan ET; Moertel CG Phase I and pharmacokinetic studies of DON. Cancer Treat. Rep. 1981, 65, 1031–1036. PubMed

Lynch G; Kemeny N; Casper E Phase II evaluation of DON (6-diazo-5-oxo-l-norleucine) in patients with advanced colorectal carcinoma. Am. J. Clin. Oncol. 1982, 5, 541–543. PubMed

Ovejera AA; Houchens DP; Catane R; Sheridan MA; Muggia FM Efficacy of 6-diazo-5-oxo-l-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice. Cancer Res. 1979, 39, 3220–3224. PubMed

Rubin J; Sorensen S; Schutt AJ; van Hazel GA; O’Connell MJ; Moertel CG A phase II study of 6-diazo-5-oxo-l-norleucine (DON, NSC-7365) in advanced large bowel carcinoma. Am. J. Clin. Oncol. 1983, 6, 325–326. PubMed

Shelton LM; Huysentruyt LC; Seyfried TN Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model. Int. J. Cancer 2010, 127, 2478–2485. PubMed PMC

Tarnowski GS; Stock CC Effects of combinations of azaserine and of 6-diazo-5-oxo-l-norleucine with purine analogues and other antimetabolites on the growth of two mouse mammary carcinomas. Cancer Res. 1957, 17, 1033–1039. PubMed

Hensley CT; Wasti AT; DeBerardinis RJ Glutamine and cancer: cell biology, physiology, and clinical opportunities. J. Clin. Invest. 2013, 123, 3678–3684. PubMed PMC

Rais R; Jancarik A; Tenora L; Nedelcovych M; Alt J; Englert J; Rojas C; Le A; Elgogary A; Tan J; Monincova L; Pate K; Adams R; Ferraris D; Powell J; Majer P; Slusher BS Discovery of 6-Diazo-5-oxo-l-norleucine (DON) prodrugs with enhanced CSF delivery in monkeys: a potential treatment for glioblastoma. J. Med. Chem. 2016, 59, 8621–8633. PubMed

Nedelcovych MT; Tenora L; Kim BH; Kelschenbach J; Chao W; Hadas E; Jancarik A; Prchalova E; Zimmermann SC; Dash RP; Gadiano AJ; Garrett C; Furtmuller G; Oh B; Brandacher G; Alt J; Majer P; Volsky DJ; Rais R; Slusher BS N-(Pivaloyloxy)alkoxy-carbonyl prodrugs of the glutamine antagonist 6-Diazo-5-oxo-l-norleucine (DON) as a potential treatment for HIV associated neurocognitive disorders. J. Med. Chem. 2017, 60, 7186–7198. PubMed PMC

Ueki N; Wang W; Swenson C; McNaughton C; Sampson NS; Hayman MJ Synthesis and preclinical evaluation of a highly improved anticancer prodrug activated by histone deacetylases and cathepsin L. Theranostics 2016, 6, 808–816. PubMed PMC

Ueki N; Lee S; Sampson NS; Hayman MJ Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease. Nat. Commun. 2013, 4, No. 2735. PubMed

Gras-Masse H Lipid vector for the delivery of peptides towards intracellular pharmacological targets. J. Mol. Recognit. 2003, 16, 234–239. PubMed

Hutchinson J; Burholt S; Hamley I Peptide hormones and lipopeptides: from self-assembly to therapeutic applications. J. Pept. Sci. 2017, 23, 82–94. PubMed PMC

Rogawski MA; Wenk GL The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev. 2003, 9, 275–308. PubMed PMC

Hubsher G; Haider M; Okun M Amantadine The journey from fighting flu to treating Parkinson disease. Neurology 2012, 78, 1096–1099. PubMed

Liu J; Obando D; Liao V; Lifa T; Codd R The many faces of the adamantyl group in drug design. Eur. J. Med. Chem. 2011, 46, 1949–1963. PubMed

Zhang W; Wang S; Wang Q; Yang Z; Pan Z; Li L Overexpression of cysteine cathepsin L is a marker of invasion and metastasis in ovarian cancer. Oncol. Rep. 2014, 31, 1334–1342. PubMed

Cui F; Wang W; Wu D; He X; Wu J; Wang M Overexpression of Cathepsin L is associated with gefitinib resistance in non-small cell lung cancer. Clin. Transl. Oncol. 2016, 18, 722–727. PubMed

Henderson JM; Zhang HE; Polak N; Gorrell MD Hepatocellular carcinoma: Mouse models and the potential roles of proteases. Cancer Lett. 2017, 387, 106–113. PubMed

Zhang Y; Fang H; Xu W Applications and modifications of 1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic acid (Tic) in peptides and peptidomimetics design and discovery. Curr. Protein Pept. Sci. 2010, 11, 752–758. PubMed

Majer P; Slaninová J; Lebl M Synthesis of methylated phenylalanines via hydrogenolysis of corresponding 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: Synthesis and biological activity of oxytocin analogues with methylated phenylalanines in position 2. Int. J. Pept. Protein Res. 1994, 43, 62–68. PubMed

Kaplan HR; Taylor D; Olson S Quinapril: overview of preclinical data. Clin. Cardiol. 1990, 13, VII-6–VII-12. PubMed

Testa B; Mayer JM Concepts in Prodrug Design To Overcome Pharmacokinetic Problems. In Pharmacokinetic Optimization in Drug Research; Testa, B. et al., Ed.; Wiley-VCH, 2001; pp 85–95.

Swindle M; Makin A; Herron A; Clubb F Jr.; Frazier K Swine as models in biomedical research and toxicology testing. Vet. Pathol. 2012, 49, 344–356. PubMed

Fu J; Pacyniak E; Leed MGD; Sadgrove MP; Marson L; Jay M Interspecies differences in the metabolism of a multi-ester prodrug by carboxylesterases. J. Pharm. Sci. 2016, 105, 989–995. PubMed PMC

Van Gelder J; Shafiee M; De Clercq E; Penninckx F; Van den Mooter G; Kinget R; Augustijns P Species-dependent and site-specific intestinal metabolism of ester prodrugs. Int. J. Pharm. 2000, 205, 93–100. PubMed

Krämer OH HDAC2: a critical factor in health and disease. Trends Pharmacol Sci. 2009, 30, 647–655. PubMed

Gondi CS; Rao JS Cathepsin B as a cancer target. Expert Opin. Ther. Targets 2013, 17, 281–291. PubMed PMC

Zhong Y-J; Shao L-H; Li Y Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review). Int. J. Oncol. 2013, 42, 373–383. PubMed PMC

Seymour LW; Ulbrich K; Steyger PS; Brereton M; Subr V; Strohalm J; Duncan R Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer 1994, 70, 636–641. PubMed PMC

Rautio J; Kumpulainen H; Heimbach T; Oliyai R; Oh D; Jarvinen T; Savolainen J Prodrugs: design and clinical applications.¨ Nat. Rev. Drug. Discovery 2008, 7, 255. PubMed

Li B; Sedlacek M; Manoharan I; Boopathy R; Duysen EG; Masson P; Lockridge O Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem. Pharmacol. 2005, 70, 1673–1684. PubMed

Zimmermann SC; Tichy T; Vávra J; Dash RP; Slusher CE; Gadiano AJ; Wu Y; Jančařík A; Tenora L; Monincova L N-substituted prodrugs of mebendazole provide improved aqueous solubility and oral bioavailability in mice and dogs. J. Med. Chem. 2018, 61, 3918–3929. PubMed

Gao P; Tchernyshyov I; Chang TC; Lee YS; Kita K; Ochi T; Zeller KI; De Marzo AM; Van Eyk JE; Mendell JT; Dang CV c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009, 458, 762–765. PubMed PMC

Discovery of tert-Butyl Ester Based 6-Diazo-5-oxo-l-norleucine Prodrugs for Enhanced Metabolic Stability and Tumor Delivery

Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug

Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be used to Monitor Target Engagement

Novel Human Neutral Sphingomyelinase 2 Inhibitors as Potential Therapeutics for Alzheimer's Disease

The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor